Clinical Practice Recommendation on Periprocedural Use of GLP-1/GIP Receptor Agonists
Semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) are both GLP-1s that function very similarly
The question remains: Is rapid weight loss worth the long-term health consequences
Zepbound and Mounjaro are identical medications both contain tirzepatide and are made by Eli Lilly
Retatrutide (LY3437943) is a first-in-class triple-receptor agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon
This phenomenon is further illustrated by results from a randomized, open-label mechanistic trial in patients with T2DM, which demonstrated that lixisenatide, with a half-life of 2 4 hours, had a significantly greater effect than liraglutide in delaying in gastric emptying and curtailing postprandial glucose excursions following a standardized solid breakfast (156)
